Fulcrum Therapeutics (FULC) Non-Current Deffered Revenue (2018 - 2021)

Fulcrum Therapeutics (FULC) has 4 years of Non-Current Deffered Revenue data on file, last reported at $1.7 million in Q4 2021.

• Non-Current Deffered Revenue for Q4 2021 came in at $1.7 million, down 43.45% year-over-year; the trailing twelve-month figure through Dec 2021 was $1.7 million (down 43.45% YoY), and the FY2021 annual result was $1.7 million, down 43.45% from the prior year.
• Non-Current Deffered Revenue grew to $1.7 million in Q4 2021 per FULC's latest filing, from $1.6 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $6.0 million in Q3 2020 and troughed at $1.4 million in Q4 2018.
• A 4-year average of $2.1 million and a median of $1.6 million in 2020 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2020 and 2021: Non-Current Deffered Revenue jumped 290.64% in 2020, then slumped 72.47% in 2021.
• A 4-year view of Non-Current Deffered Revenue shows it stood at $1.4 million in 2018, then climbed by 11.2% to $1.6 million in 2019, then soared by 90.57% to $3.0 million in 2020, then plunged by 43.45% to $1.7 million in 2021.
• Business Quant data shows FULC's Non-Current Deffered Revenue at $1.7 million in Q4 2021, $1.6 million in Q3 2021, and $1.7 million in Q2 2021.